Sin beneficio de la Quimioterapia en el
grupo
c-High
/
MP-Low
Allocated
Treatment strategy
% at 5 Year(s)
(95% CI)
Hazard Ratio
(95% CI)
p-value
(adjusted
logrank)
ACT
95.9 (94.0, 97.2)
1.00
0.154
no ACT
94.4 (92.3, 95.9)
1.52 (0.86, 2.71)
There was no statistically significant or clinically meaningful benefit of adding chemotherapy to
this group of clinically high risk / MammaPrint Low Risk patients
